Immune-Related Adverse Events Involving Multiple Organ Sites in a Patient Treated With Nivolumab Plus Ipilimumab.

Abstract

A 56-year-old white man with a 74 pack-year smoking history presented with macroscopic hematuria and a significant weight loss of 45 pounds in 6 months. His clinical laboratory tests indicated iron defi ciency anemia and a computed tomography (CT) scan showed a left kidney tumor, mediastinal lymph nodes, and multiple lung metastases. A percutaneous CT-guided kidney biopsy revealed grade 3 clear cell renal carcinoma based on World Health Organization/International Society of Urologic Pathology classifi cation. The patient started first line systemic treatment for intermediate-risk metastatic renal cell carcinoma (mRCC) with combination immunotherapy with nivolumab plus ipilimumab.1 After 10 days of the first cycle, he presented with a pruritic maculopapular rash covering 20% of his body surface.

• Authors: Yuly A Remolina-Bonilla, Brenda Jimenez-Franco, Elaine T Lam, Maria T Bourlon
• Journal: Oncology (Williston Park, N.Y.) (Oncology (Williston Park)) Vol. 34 Issue 5 Pg. 171-174 (May 13 2020) ISSN: 0890-9091 [Print] United States
• PMID: 32644176 (Publication Type: Case Reports)

Chemical References

• Anti-Inflammatory Agents
• Ipilimumab
• Nivolumab
• Prednisone

Topics

• Anti-Inflammatory Agents (administration & dosage)
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Carcinoma, Renal Cell (drug therapy, immunology, pathology)
• Humans
• Immunotherapy (methods)
• Ipilimumab (administration & dosage, adverse effects)
• Kidney Neoplasms (drug therapy, immunology, pathology)
• Lung Neoplasms (drug therapy, immunology, secondary)
• Lymphatic Metastasis
• Male
• Middle Aged
• Nephritis, Interstitial (chemically induced, drug therapy, pathology)
• Nivolumab (administration & dosage, adverse effects)
• Prednisone (administration & dosage)
• Treatment Outcome